Download PDF BrochureInquire Before Buying
The Preimplantation Genetic Testing (PGT) market in Spain focuses on advanced reproductive technology used alongside in vitro fertilization (IVF). Essentially, it involves genetic screening of embryos before they are implanted in the uterus. This is done to check for chromosomal abnormalities or specific inherited genetic disorders, giving prospective parents a way to increase the chances of a successful pregnancy and have a child free from known genetic issues, especially for older women or couples with a family history of such conditions.
The Preimplantation Genetic Testing Market in Spain is anticipated to grow steadily at a CAGR of XX% from 2025 to 2030, rising from an estimated US$ XX billion in 2024–2025 to US$ XX billion by 2030.
The global preimplantation genetic testing market is valued at $636.4 million in 2024, projected to reach $690.2 million in 2025, and is expected to hit $1,135.0 million by 2030, growing at a CAGR of 10.5%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
Drivers
The high success rate and global reputation of Spain’s assisted reproductive technology (ART) clinics act as a major market driver for Preimplantation Genetic Testing (PGT). Spain is a leading destination for fertility tourism, and PGT is routinely offered to improve IVF outcomes. The country’s favorable legal framework, coupled with advanced clinical expertise, attracts both domestic and international patients seeking comprehensive genetic screening to select viable embryos and reduce the risk of transferring embryos with chromosomal abnormalities or single-gene disorders, thereby boosting demand.
The increasing average maternal age at first birth in Spain is significantly propelling the demand for PGT. As women delay childbearing, the incidence of age-related chromosomal abnormalities, such as aneuploidy, rises. PGT technologies like Preimplantation Genetic Screening (PGS) are critical for these older patients to maximize their chances of a successful pregnancy by identifying genetically healthy embryos. This demographic shift makes advanced genetic testing an indispensable part of routine IVF procedures for a large segment of the patient population.
Growing public and professional awareness regarding genetic health and inherited diseases drives market expansion. Educational efforts and increased accessibility to genetic counseling encourage prospective parents, especially those with a family history of genetic disorders, to opt for Preimplantation Genetic Diagnosis (PGD). The desire to prevent the transmission of severe monogenic diseases, such as cystic fibrosis or Huntington’s disease, fuels the need for specialized PGT services, solidifying its adoption across Spanish fertility centers.
Restraints
One primary restraint is the high cost associated with PGT procedures, which often presents a significant financial burden for patients. While ART treatments are common, PGT often involves substantial additional expense that may not be fully covered by the public healthcare system or private insurance, limiting accessibility. The high costs of specialized reagents, instruments, and the labor-intensive nature of embryo biopsy and genetic analysis can deter many couples from pursuing PGT, despite the clinical benefits.
Ethical and societal debates surrounding genetic testing and embryo selection pose a restraint on the market’s growth potential. Although Spain’s legislation is generally permissive regarding PGT for medical reasons, moral concerns about embryo disposal and the concept of “designer babies” influence public opinion and sometimes governmental policies. These ethical considerations can lead to hesitation among clinics and patients, especially concerning tests for non-medical traits, thereby slowing the rapid adoption of PGT services.
Technical challenges related to embryo biopsy and the potential for mosaicism restrain the market. The procedure of safely removing cells from a fragile embryo requires highly specialized skills, and any error can compromise the embryo’s viability. Furthermore, the detection of mosaicism (where an embryo contains both normal and abnormal cells) can complicate interpretation and clinical decision-making, leading to uncertainty and making standardized procedures for PGT more difficult to implement consistently across different clinics.
Opportunities
The continuous technological advancements, particularly in Next-Generation Sequencing (NGS) and Non-Invasive PGT (NiPGT), create significant market opportunities. NGS allows for higher throughput and accuracy in detecting chromosomal abnormalities (PGS), making the procedure more reliable. NiPGT, which tests DNA released into the culture medium without needing a biopsy, promises to reduce risks to the embryo and simplify the procedure, potentially lowering costs and expanding PGT’s appeal to a broader patient base in Spain.
Expanding the application of PGT beyond routine infertility cases to include HLA typing offers a compelling growth opportunity. HLA typing is used to identify embryos that can serve as a suitable match for an existing child suffering from a life-threatening disease, such as leukemia. As Spanish society seeks advanced therapeutic solutions for children requiring bone marrow transplants, PGT-HLA matching offers a specialized, high-value service that can drive clinical and commercial interest in the market.
The focus on standardizing PGT procedures and protocols across clinics provides a strong opportunity for industry consolidation and quality improvement. Developing standardized protocols for biopsy, sample handling, and analysis can increase reliability and minimize discrepancies in results. Companies that offer comprehensive, certified solutions and training that adhere to stringent quality control standards will be well-positioned to capitalize on the increasing demand for consistent and trustworthy PGT services in Spain’s competitive ART landscape.
Challenges
A significant challenge is the critical need for highly specialized personnel, including skilled embryologists and genetic counselors. Performing embryo biopsy and interpreting complex genetic data require extensive training and expertise that are not uniformly available across all Spanish fertility clinics. The shortage of qualified professionals can constrain the capacity of clinics to perform PGT efficiently, leading to potential bottlenecks in service delivery and limiting the market’s potential for scalability.
Regulatory hurdles related to the approval and validation of new PGT tests present a logistical challenge. Although Spain has a progressive regulatory environment for ART, novel genetic testing methodologies and instrumentation require rigorous validation and conformity assessment before widespread clinical use. Navigating these regulatory pathways, especially for new diagnostic technologies like NiPGT, can be time-consuming and expensive, delaying the introduction of cutting-edge solutions to the market.
The challenge of integrating PGT services into established clinical workflows smoothly is notable, especially in smaller, independent fertility centers. PGT involves coordination between embryology labs, genetics labs, and clinical teams, requiring sophisticated data management systems and seamless communication. The investment in new infrastructure and the necessary retraining of clinical staff to incorporate PGT effectively into their existing protocols can be a barrier for clinics with limited resources.
Role of AI
Artificial Intelligence (AI) plays an emerging role in optimizing embryo selection, moving beyond manual morphological grading. AI-powered image analysis algorithms can automatically assess large datasets of time-lapse images (morphokinetics) from embryos to identify subtle markers correlated with genetic normality and implantation potential. By providing objective and highly reproducible scoring, AI enhances the accuracy of choosing the best embryos for transfer, complementing PGT results and thus improving overall IVF success rates in Spanish clinics.
AI significantly contributes to the efficiency and precision of genetic data interpretation in PGT. The analysis of complex sequencing data from PGT samples, particularly in PGS for aneuploidy screening, involves evaluating thousands of data points. Machine learning models can process this complex genomic information rapidly, automating the detection of chromosomal imbalances or single-gene mutations with higher accuracy than manual review, which speeds up diagnosis and reporting times for Spanish genetic laboratories.
The integration of AI can improve laboratory workflow automation and quality control within PGT labs. AI systems can monitor various operational parameters, such as culture conditions and instrument performance, in real-time to detect anomalies. This autonomous monitoring ensures optimal environmental conditions for embryo development and minimizes human error in handling and analysis. Enhanced automation through AI increases the reliability and throughput of PGT procedures offered by Spanish ART centers.
Latest Trends
The shift towards Non-Invasive Preimplantation Genetic Testing (NiPGT) is a dominant trend in Spain. This emerging technique analyzes cell-free DNA released by the embryo into the culture medium, eliminating the need for an invasive biopsy. NiPGT is gaining attention as it reduces the risk of harming the embryo and simplifies the procedure, potentially making PGT more accessible and appealing to a wider range of patients seeking safer, less intrusive genetic assessment methods in Spanish fertility clinics.
There is a growing trend toward using advanced, next-generation sequencing (NGS) platforms for PGT, replacing older technologies like FISH and aCGH. NGS provides much higher resolution for detecting segmental and whole-chromosome aneuploidies, as well as mosaicism, offering more comprehensive genetic information. This move ensures greater accuracy and robustness of the testing results, aligning Spanish PGT practices with international high-resolution genomic analysis standards, particularly for complex cases.
The increasing adoption of comprehensive PGT panels that screen for both aneuploidies (PGS) and specific single-gene disorders (PGD) simultaneously represents a key trend. Clinics are moving toward integrated testing to offer a holistic genetic profile of the embryo, maximizing the information available to parents and clinicians. This integrated approach caters to couples facing both age-related risks and known inherited conditions, enhancing the value proposition of PGT services in Spain’s competitive fertility market.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605